-
Featured Authors
-
Archives
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: healthcare
Biopharmaceuticals and Accountable Care Organizations: Balancing Cost and Quality
As biopharmaceutical manufacturers consider the new reality of accountable care organizations (ACOs) and the impact on their businesses, they must be ready to demonstrate the value of their products in ways that recognize the fine balance of cost and quality that ACO and ACO-like models seek to achieve. According to panelists speaking at the 2013 BIO International Convention session entitled, “Accountable Care Organization (ACO) Framework for Biopharmaceuticals,” there are three primary considerations when it comes Read More >
The Affordable Care Act is Here to Stay
The Patient Protection and Affordable Care Act (ACA) of 2010 includes provisions that could lead to new and improved treatments, cures and cost savings for patients. All of these changes, however, will impact the biotechnology industry and the future of patient access to needed medicines. In an expert panel at the 2013 BIO International Convention moderated by BioCentury’s Steve Usdin, multiple stakeholders addressed key elements of the ACA focused on both the value the ACA Read More >
The Rise of Specialty Pharmaceuticals
Fact: Specialty pharmaceuticals represented nearly 25 percent of all drug spending last year. By 2018, it’s estimated they’ll account for nearly half of the 100 top-selling medications on the market. With an average cost for a specialty medical therapy hovering around $35,000 to $75,000 per patient per year, this is an area that is getting the attention of top industry players – from biopharma who see the market opportunity to healthcare payors like health plans Read More >
The Ethics of the Market Access Debate
At the core of the market access conversation lies the question of value. How much do we value two years added to the end of an 80-year-old’s life? How do we put a dollar amount on a medicine that prevents a rare disease patient, who may only live to age 20 regardless of receiving treatment, from losing her ability to walk? How can we define metrics to measure the cost of a child with a Read More >
Managed Entry Trumps Risk Sharing
Since 2000, pharmaceu-tical and biotech companies have engaged in agreements with government and private payers across the world to gain market access for their innovative drugs despite struggles to qualify for formal reimbursement criteria, such as the cost effectiveness threshold from NICE in the UK. These agreements, usually referred to as “risk sharing” agreements, have had a wide variety of structures but usually do not involve any sharing of risk, as the name misleadingly suggests. Read More >
